Skip to content

COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504179-26-00
Enrollment
24
Registered
2023-06-23
Start date
2024-07-19
Completion date
2025-04-10
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Venous Thromboembolism

Brief summary

The primary outcome is the rate of adjudicated clinically relevant bleeding (CRB) events defined as the composite of major bleeding (MB) events and/or clinically relevant non-major bleeding events (CRNMB).

Detailed description

a) adjudicated MB events; b) adjudicated CRNMB events; c) adjudicated recurrent VTE events; d) adjudicated VTE-related deaths; e) all-cause mortality; f) medication adherence; g) incremental cost-effectiveness ratios, including cost per one CRB case prevented, cost per one life year saved and cost per one quality-adjusted life year (QALY) gained; h) impact of verbal consent on patient participation in comparison with participants from sites using written informed consent.

Interventions

Sponsors

Royal College Of Surgeons In Ireland, Royal College Of Surgeons In Ireland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary outcome is the rate of adjudicated clinically relevant bleeding (CRB) events defined as the composite of major bleeding (MB) events and/or clinically relevant non-major bleeding events (CRNMB).

Secondary

MeasureTime frame
a) adjudicated MB events; b) adjudicated CRNMB events; c) adjudicated recurrent VTE events; d) adjudicated VTE-related deaths; e) all-cause mortality; f) medication adherence; g) incremental cost-effectiveness ratios, including cost per one CRB case prevented, cost per one life year saved and cost per one quality-adjusted life year (QALY) gained; h) impact of verbal consent on patient participation in comparison with participants from sites using written informed consent.

Countries

Ireland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026